Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35151415

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Mar
First author
Richardson PG

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Apr;23(4):e161. doi: 10.1016/S1470-2045(22)00131-0.
    note
    Source null
    related pmid
    35358464
    relationship
    Erratum in
  2. citation
    Lancet Oncol. 2022 Sep;23(9):e404. doi: 10.1016/S1470-2045(22)00493-4.
    note
    Source null
    related pmid
    36055308
    relationship
    Erratum in

Authors and identifiers

  1. name
    Richardson PG
    type
    Author
  2. name
    Perrot A
    type
    Author
  3. name
    San-Miguel J
    type
    Author
  4. name
    Beksac M
    type
    Author
  5. name
    Spicka I
    type
    Author
  6. name
    Leleu X
    type
    Author
  7. name
    Schjesvold F
    type
    Author
  8. name
    Moreau P
    type
    Author
  9. name
    Dimopoulos MA
    type
    Author
  10. name
    Huang JS
    type
    Author
  11. name
    Minarik J
    type
    Author
  12. name
    Cavo M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Richardson PG
    type
    Author
  2. name
    Perrot A
    type
    Author
  3. name
    San-Miguel J
    type
    Author
  4. name
    Beksac M
    type
    Author
  5. name
    Spicka I
    type
    Author
  6. name
    Leleu X
    type
    Author
  7. name
    Schjesvold F
    type
    Author
  8. name
    Moreau P
    type
    Author
  9. name
    Dimopoulos MA
    type
    Author
  10. name
    Huang JS
    type
    Author
  11. name
    Minarik J
    type
    Author
  12. name
    Cavo M
    type
    Author
bibliography ids
  1. nci-bib-e5a4d5d6646168c720da9911
book metadata
content sha256
1fd486037e7cf87752c7cd351790cb846b265498953228c3475613a65ee77ee3
document type
citation
dois
  1. 10.1016/S1470-2045(22)00019-5
electronic publication date
display
2022 Feb 10
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35151415
immutable id
pubmed:35151415@1fd486037e7cf87752c7cd351790cb846b265498953228c3475613a65ee77ee3
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
3
name
The Lancet. Oncology
nlm unique id
100957246
pages
416-427
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Apr;23(4):e161. doi: 10.1016/S1470-2045(22)00131-0.
    note
    Source null
    related pmid
    35358464
    relationship
    Erratum in
  2. citation
    Lancet Oncol. 2022 Sep;23(9):e404. doi: 10.1016/S1470-2045(22)00493-4.
    note
    Source null
    related pmid
    36055308
    relationship
    Erratum in
outcomes validated
false
pmid
35151415
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
a1f3e260c8da1031be39131da512c365a09c426f1e155a414fe37e9f436d00d4
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Mar
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35151415/
title
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.

Preserved source evidence · Not medical advice